Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 8/20 | 0.50 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7488073 | 0.89 | TOP2A (0.50) | TOP2ATOP2BPOLBSMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL10925309 | 0.88 | TOP2A (0.49) | TOP2ATOP2BPOLBSMN1; SMN2NPC1 | |
| SCHEMBL11748467 | 0.86 | TOP2A (0.57) | TOP2ATOP2BPOLBSMN1; SMN2NPC1 | |
| SCHEMBL10810013 | 0.85 | TOP2A (0.48) | TOP2ATOP2BPOLBSMN1; SMN2NPC1 | |
| SCHEMBL11750031 | 0.85 | TOP2A (0.54) | TOP2ATOP2BPOLBSMN1; SMN2NPC1 | |
| SCHEMBL6750941 | 0.85 | TOP2A (0.47) | TOP2ATOP2BPOLBSMN1; SMN2NPC1 | |
| SCHEMBL7503128 | 0.85 | TOP2A (0.49) | TOP2ATOP2BPOLBSMN1; SMN2NPC1 | |
| SCHEMBL10815975 | 0.84 | TOP2A (0.49) | TOP2ATOP2BPOLBSMN1; SMN2NPC1 | |
| SCHEMBL10813022 | 0.84 | TOP2A (0.47) | TOP2ATOP2BPOLBSMN1; SMN2NPC1 | |
| SCHEMBL10813252 | 0.84 | TOP2A (0.45) | TOP2ATOP2BPOLBSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 476 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746969-A1 | HETEROCYCLIC PAD4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122094961-A | DNA-dependent protein kinase inhibitors and compositions based on 5, 6-core silacycle and their use in gene editing | — | 2026-05-26 | — | — | CN | claimed |
| WO-2025049247-A1 | 5,6-CORE SILACYCLE BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING | JUNO THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | claimed |
| CN-115297930-B | Antimicrobial compounds and methods | 库扎环球有限责任公司 | 2025-02-14 | — | — | CN | claimed |
| WO-2025024288-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-30 | — | — | WO | claimed |
| CN-119364736-A | Multilayer composite film with light transmission, infrared stealth and electromagnetic shielding functions and preparation method thereof | 天目山实验室 | 2025-01-24 | — | — | CN | claimed |
| CN-119325392-A | Phenyl maleimide linker | 萤火虫生物股份有限公司 | 2025-01-17 | — | — | CN | claimed |
| WO-2023245150-A9 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-01-16 | — | — | WO | claimed |
| EP-4489792-A1 | PHENYL MALEIMIDE LINKER AGENTS | Firefly Bio, Inc. (US) | 2025-01-15 | — | — | EP | claimed |
| EP-4157837-B1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2024-12-18 | — | — | EP | claimed |
| CN-115297930-A | Antimicrobial compounds and methods | 库扎环球有限责任公司 | 2022-11-04 | — | — | CN | claimed |
| CN-110759893-B | Hyrtinadine alkaloid derivative, preparation method thereof and application thereof in resisting plant viruses and germs | 南开大学 | 2022-10-28 | — | — | CN | claimed |
| CN-115181164-A | Derivatives of amatoxins and their coupling to cell binding molecules | 杭州多禧生物科技有限公司 | 2022-10-14 | — | — | CN | claimed |
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | Anhui Newstar Pharmaceutical Development Co., Ltd. (CN) | 2022-09-08 | — | — | US | claimed |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | claimed |
| EP-3966208-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | Antidote IP Holdings, LLC (US) | 2022-03-16 | — | — | EP | claimed |
| WO-2022042657-A1 | COMPOUNDS AND METHODS OF USE | Ferro Therapeutics, Inc. (US) | 2022-03-03 | — | — | WO | claimed |
| US-4505925-A | ANTITUMOR | WARNER-LAMBERT COMPANY (US) | 1985-03-19 | — | — | US | claimed |
| EP-0127389-A2 | N,N-diethyl-5-methyl-2H-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor | WARNER-LAMBERT COMPANY (US) | 1984-12-05 | — | — | EP | claimed |
| US-3963740-A | PARASITICIDE | PARKE, DAVIS & COMPANY (US) | 1976-06-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | AHR, ARNT, HMOX1 | TOP2A 1185/4885TOP2B 1396/4885POLB 3295/4885 |
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | MST1, MSTN, MST1R | TOP2A 631/4885TOP2B 1152/4885POLB 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.